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Objective
To simultaneously load drug and encapsulate the drug in a high throughput, massively-arrayed microfluidic
type system using a patented Chemtor fiber technology.
Motivation
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues
associated with conventional therapeutic agents, including their poor water solubility (at least, for most
anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic
index.
Trends in the development of 
nanomedicines
List of FDA-approved nanomedicines stratified by material 
category 
Name Material  
Description 
Nanoparticle 
Advantage 
Indication(s) Year(s) 
approved 
Polymer Nanoparticles – synthetic polymer particles combined with drugs or biologics 
Cimzia®/certolizumab
pegol (UCB) 
PEGylated antibody fragment 
(Certolizumab) 
Improved circulation time 
and greater stability in vivo. 
Crohn's disease 
Rheumatoid 
arthritis 
Psoriatic 
Arthritis 
Ankylosing 
Spondylitis 
2008 
2009 
2013 
2013 
Plegridy® 
(Biogen) 
Polymer-protein conjugate 
(PEGylated IFN beta-1a)
Improved stability of protein 
through 
PEGylation
Multple
Sclerosis 
2014
ADYNOVATE 
(Baxalta) 
Polymer-protein conjugate 
(PEGylated factor VIII) 
Improved stability of protein 
through 
PEGylation
Hemophilia 2015
Liposome formulations combined with drugs or biologics 
Marqibo® (Onco TCS) Liposomal Vincristine Increased delivery to tumour site; 
lower systemic toxicity arising 
from side-effects
Acute 
Lymphoblastic 
Leukemia 
2012
Onivyde® (Merrimack) Liposomal Irinotecan Increased delivery to tumour site; 
lower systemic toxicity arising 
from side-effects 
Pancreatic 
Cancer 
2015
Micellar nanoparticles combined with drugs or biologics 
Estrasorb™(Novavax) Micellar Estradiol Controlled delivery of 
therapeutic 
Menopausal 
therapy 
2003
Protein nanoparticles combined with drugs or biologics 
Abraxane®/ABI-007
(Celgene) 
Albumin-bound paclitaxel 
nanoparticles 
Improved solubility; improved 
delivery to tumor
Breast cancer 
NSCLC 
Pancreatic 
cancer 
2005 
2012 
2013 
Nanocrystals
Avinza® (Pfizer) Morphine sulfate Increased drug loading and 
bioavailability; extended release 
Psychostimula
nt
2002 
(2015) 
Ryanodex® 
(Eagle Pharmaceuticals) 
Dantrolene sodium Faster administration at higher 
doses 
Malignant 
hypothermia 
2014
Inorganic and metallic nanoparticles 
Nanotherm® 
(MagForce) 
Iron oxide Allows cell uptake and introduces 
Superparamagnetism
Glioblastoma 2010 
Delivery efficiency and consequences
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